Latest news with #CompensationCommittee
Yahoo
8 hours ago
- Business
- Yahoo
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the 'Company') (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the 'Compensation Committee') granted inducement awards consisting of nonstatutory stock options to purchase 79,200 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price equal to $6.30 per share, the Company's closing sales price on June 2, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company's 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration ('FDA') for the treatment of relapsed/refractory ('R/R') NPM1-mutant acute myeloid leukemia ('AML'). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA's acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn. Contacts Investors:Patti BankManaging Director(415) Media:media@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Bloomberg
3 days ago
- Business
- Bloomberg
Warner Bros. Shareholders Reject Advisory Vote on Executive Pay
A majority of Warner Bros. Discovery Inc. shareholders voted against the 2024 compensation package given to Chief Executive Officer David Zaslav and other executives at the company's annual meeting Monday, according to a regulatory filing. 'The Warner Bros. Discovery Board of Directors appreciates the views of all its shareholders and takes the results of the annual advisory vote on executive compensation seriously,' the board of directors said in a statement. 'The Compensation Committee of the Board looks forward to continuing its regular practice of engaging in constructive dialog with our shareholders.'
Globe and Mail
4 days ago
- Business
- Globe and Mail
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.28 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employees' continued service to Zentalis on each vesting date. About Zentalis Pharmaceuticals Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
Business Wire
4 days ago
- Business
- Business Wire
Cornerstone Building Brands Appoints Suzanne Stefany to Its Board of Directors
BUSINESS WIRE)--Cornerstone Building Brands, Inc., a leading manufacturer of exterior building products in North America, has appointed Suzanne Stefany as a member of its board of directors (the 'Board'), effective June 1, 2025. Suzanne will serve on the Board's Nominating and Corporate Governance and Compensation Committees. 'Suzanne's deep strategic expertise and building materials industry knowledge, combined with her board experience, will be invaluable as we focus on being the partner of choice for customers and delivering top-tier growth and margins over the long term,' Share Suzanne is a Senior Advisor at PJT Partners, an advisory-focused investment bank headquartered in New York City, having previously served as a Partner from 2017 to 2024. At PJT Partners, Suzanne advises companies in the industrials space on global corporate transformations and complex situations. She brings extensive leadership experience in finance, corporate governance and capital markets, as well as a diverse business acumen. 'Suzanne's deep strategic expertise and building materials industry knowledge, combined with her board experience, will be invaluable as we focus on being the partner of choice for customers and delivering top-tier growth and margins over the long term,' said John Krenicki, Chairman and Interim President and Chief Executive Officer, Cornerstone Building Brands. 'We are excited to welcome her to our Board of Directors.' Prior to joining PJT Partners, Suzanne served as Managing Director, Global Industry Analyst at Wellington Management, where she managed global portfolio mandates across the U.S., Europe and Asia. Earlier in her career, she held leadership roles at Loomis Sayles, Invesco Capital Management and Putnam Investments. Suzanne has served on the board of directors for AMETEK since 2022, where she is a member of the Audit Committee, Compensation Committee and Governance Committee. Suzanne previously served on the board of directors of JELD-WEN, where she served as Lead Independent Director, Chair of the Nominating and Governance Committee and a member of the Compensation Committee. Suzanne holds a bachelor's degree in Economics and Spanish from Tufts University and a master's degree in Management and Finance from the MIT Sloan School of Management. About Cornerstone Building Brands Cornerstone Building Brands is a leading manufacturer of exterior building products for residential and low-rise non-residential buildings in North America. Headquartered in Cary, N.C., we serve residential and commercial customers across the new construction and Repair & Remodel (R&R) markets. Our market-leading portfolio of products spans vinyl windows, vinyl siding, stone veneer, metal roofing, metal wall systems and metal accessories. Cornerstone Building Brands' broad, multi-channel distribution platform and expansive national footprint includes more than 18,800 team members at manufacturing, distribution and office locations throughout North America. Corporate stewardship and Environmental, Social and Governance (ESG) responsibility are embedded in our culture. We are committed to contributing positively to the communities where we live, work and play. For more information, visit us at
Yahoo
23-05-2025
- Business
- Yahoo
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif., May 23, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on May 19, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to four new employees to purchase, in aggregate, up to 8,300 shares of Company common stock. The Company's independent Compensation Committee approved these awards as an inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $17.13 per share, which is equal to the closing price of the Company's common stock on May 19, 2025, and all will be subject to time-based vesting over four years, with 1/4 of each award vesting annually, subject to the employee's continued employment with Pulse Biosciences. The options are subject to the terms and conditions of the 2017 Inducement Equity Incentive Plan and the award agreements entered into with each recipient. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. View source version on Contacts Investors: Pulse Biosciences, Skinner, CFOIR@ Or Gilmartin GroupPhilip Trip Taylor415.937.5406philip@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
